IL106306A - Rotavirus vaccines for injection - Google Patents
Rotavirus vaccines for injectionInfo
- Publication number
- IL106306A IL106306A IL10630693A IL10630693A IL106306A IL 106306 A IL106306 A IL 106306A IL 10630693 A IL10630693 A IL 10630693A IL 10630693 A IL10630693 A IL 10630693A IL 106306 A IL106306 A IL 106306A
- Authority
- IL
- Israel
- Prior art keywords
- vaccine
- virus
- rotavirus
- compositions according
- inoculated
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 159
- 241000702670 Rotavirus Species 0.000 title claims abstract description 76
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 230000003053 immunization Effects 0.000 title claims abstract description 17
- 238000002649 immunization Methods 0.000 title description 10
- 241000700605 Viruses Species 0.000 claims abstract description 120
- 241001465754 Metazoa Species 0.000 claims abstract description 22
- 238000011081 inoculation Methods 0.000 claims abstract description 13
- 206010067470 Rotavirus infection Diseases 0.000 claims abstract description 12
- 229940031626 subunit vaccine Drugs 0.000 claims abstract description 11
- 229940031551 inactivated vaccine Drugs 0.000 claims abstract description 4
- 229940124859 Rotavirus vaccine Drugs 0.000 claims description 10
- 241000617996 Human rotavirus Species 0.000 claims description 9
- 230000000474 nursing effect Effects 0.000 claims description 9
- 230000032696 parturition Effects 0.000 claims 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 94
- 239000002671 adjuvant Substances 0.000 description 60
- 230000000968 intestinal effect Effects 0.000 description 30
- 238000002255 vaccination Methods 0.000 description 27
- 230000002953 anti-rotaviral effect Effects 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 21
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 230000029142 excretion Effects 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000002779 inactivation Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 229940037003 alum Drugs 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940126578 oral vaccine Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 241000702678 Simian rotavirus A/SA11 Species 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000011555 rabbit model Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 239000012646 vaccine adjuvant Substances 0.000 description 3
- 229940124931 vaccine adjuvant Drugs 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 206010017913 Gastroenteritis rotavirus Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000702648 Rabbit rotavirus Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229960000380 propiolactone Drugs 0.000 description 2
- 108700010850 rotavirus proteins Proteins 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 101710138767 Non-structural glycoprotein 4 Proteins 0.000 description 1
- 101710144128 Non-structural protein 2 Proteins 0.000 description 1
- 101710144111 Non-structural protein 3 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000001983 lactogenic effect Effects 0.000 description 1
- 229940038523 live rotavirus vaccine Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000310 rehydration solution Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Catalysts (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/911,593 US6780630B1 (en) | 1992-07-10 | 1992-07-10 | Parenteral immunization against rotavirus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL106306A0 IL106306A0 (en) | 1993-11-15 |
| IL106306A true IL106306A (en) | 2002-07-25 |
Family
ID=25430523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10630693A IL106306A (en) | 1992-07-10 | 1993-07-12 | Rotavirus vaccines for injection |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6780630B1 (de) |
| EP (1) | EP0603386B1 (de) |
| JP (1) | JPH07501558A (de) |
| KR (2) | KR940702388A (de) |
| AT (1) | ATE211923T1 (de) |
| AU (1) | AU673370B2 (de) |
| CA (1) | CA2116971A1 (de) |
| DE (1) | DE69331459T2 (de) |
| DK (1) | DK0603386T3 (de) |
| ES (1) | ES2166763T3 (de) |
| IL (1) | IL106306A (de) |
| NO (1) | NO307815B1 (de) |
| PT (1) | PT603386E (de) |
| WO (1) | WO1994001134A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5626851A (en) * | 1987-11-30 | 1997-05-06 | The Wistar Institute Of Anatomy And Biology | Rotavirus reassortant vaccine |
| US6210677B1 (en) * | 1993-01-29 | 2001-04-03 | Robert C. Bohannon | Method to reduce the physiologic effects of drugs on mammals |
| US6673355B1 (en) | 1995-06-14 | 2004-01-06 | Baylor College Of Medicine | Rotavirus enterotoxin NSP4 and methods of using same |
| US6210682B1 (en) | 1995-06-14 | 2001-04-03 | Baylor College Of Medicine | Rotavirus enterotoxin NSP4 and methods of using same |
| CN101835488B (zh) | 2007-09-04 | 2018-10-26 | 美国政府(由卫生和人类服务部、疾病控制和预防中心的部长所代表) | 轮状病毒的热灭活 |
| EP3427750A1 (de) | 2009-05-12 | 2019-01-16 | The Government of The United States of America as represented by The Secretary, Department of Health and Human Services | Neue humane rotavirenstämme und impfstoffe |
| EP3169313B1 (de) * | 2014-07-18 | 2019-08-28 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Thermostabile gefriergetrocknete rotavirusimpfstoffformulierung und verfahren zur herstellung davon |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2483779A1 (fr) * | 1980-06-05 | 1981-12-11 | Synthelabo | Procede pour isoler des antigenes glycoproteiques viraux et son application a la preparation de vaccins |
| US4341763A (en) * | 1981-03-10 | 1982-07-27 | Smithkline-Rit | Methods of vaccinating humans against rotavirus infection |
| US4636385A (en) * | 1985-02-15 | 1987-01-13 | The Wistar Institute Of Anatomy & Biology | Vaccine, method for its preparation, and use thereof in vaccinating humans against rotavirus infection |
| US4861864A (en) * | 1985-05-14 | 1989-08-29 | Albert Einstein College of Medicine of Yeshiva University (a Div. of Yeshiva University) | Rotavirus antigens |
| US4704275A (en) * | 1985-08-26 | 1987-11-03 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against rotavirus diseases |
| EP0251467A3 (de) * | 1986-06-20 | 1988-07-20 | Abbott Laboratories | Zusammensetzungen und Verfahren zum Gebrauch eines Haupt-Aussen-Kapsid-Proteins (VP7) des Rotavirus SA-11 |
| US4927628A (en) * | 1987-09-21 | 1990-05-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against rotavirus diseases and method of preparing same |
| US5147639A (en) * | 1990-06-19 | 1992-09-15 | Ambico, Inc. | Type-c rotavirus cultures and uses therefor |
| JP2753393B2 (ja) * | 1990-11-16 | 1998-05-20 | チルドレンズ ホスピタル メディカル センター | ヒトロタウイルス，ワクチンおよび方法 |
-
1992
- 1992-07-10 US US07/911,593 patent/US6780630B1/en not_active Expired - Fee Related
-
1993
- 1993-07-12 PT PT93917119T patent/PT603386E/pt unknown
- 1993-07-12 IL IL10630693A patent/IL106306A/en not_active IP Right Cessation
- 1993-07-12 KR KR1019940700778A patent/KR940702388A/ko not_active Application Discontinuation
- 1993-07-12 AT AT93917119T patent/ATE211923T1/de not_active IP Right Cessation
- 1993-07-12 DE DE69331459T patent/DE69331459T2/de not_active Expired - Fee Related
- 1993-07-12 EP EP93917119A patent/EP0603386B1/de not_active Revoked
- 1993-07-12 ES ES93917119T patent/ES2166763T3/es not_active Expired - Lifetime
- 1993-07-12 CA CA002116971A patent/CA2116971A1/en not_active Abandoned
- 1993-07-12 AU AU46740/93A patent/AU673370B2/en not_active Ceased
- 1993-07-12 WO PCT/US1993/006543 patent/WO1994001134A1/en not_active Application Discontinuation
- 1993-07-12 KR KR1020017006840A patent/KR100354587B1/ko not_active IP Right Cessation
- 1993-07-12 JP JP6503564A patent/JPH07501558A/ja not_active Ceased
- 1993-07-12 DK DK93917119T patent/DK0603386T3/da active
-
1994
- 1994-03-09 NO NO940827A patent/NO307815B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69331459T2 (de) | 2002-06-20 |
| EP0603386A4 (en) | 1996-05-29 |
| ATE211923T1 (de) | 2002-02-15 |
| AU4674093A (en) | 1994-01-31 |
| NO940827D0 (no) | 1994-03-09 |
| ES2166763T3 (es) | 2002-05-01 |
| EP0603386B1 (de) | 2002-01-16 |
| EP0603386A1 (de) | 1994-06-29 |
| JPH07501558A (ja) | 1995-02-16 |
| WO1994001134A1 (en) | 1994-01-20 |
| AU673370B2 (en) | 1996-11-07 |
| US6780630B1 (en) | 2004-08-24 |
| NO307815B1 (no) | 2000-06-05 |
| IL106306A0 (en) | 1993-11-15 |
| PT603386E (pt) | 2002-06-28 |
| NO940827L (no) | 1994-05-09 |
| CA2116971A1 (en) | 1994-01-20 |
| KR940702388A (ko) | 1994-08-20 |
| KR100354587B1 (ko) | 2002-10-04 |
| DE69331459D1 (de) | 2002-02-21 |
| DK0603386T3 (da) | 2002-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Conner et al. | Rotavirus vaccine administered parenterally induces protective immunity | |
| Clark et al. | Rotavirus isolate WI61 representing a presumptive new human serotype | |
| Conner et al. | Rabbit model of rotavirus infection | |
| Hoshino et al. | Infection immunity of piglets to either VP3 or VP7 outer capsid protein confers resistance to challenge with a virulent rotavirus bearing the corresponding antigen | |
| Isolauri et al. | Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG | |
| Feng et al. | Comparison of mucosal and systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus | |
| Kapikian et al. | Rotavirus: the major etiologic agent of severe infantile diarrhea may be controllable by a Jennerian approach to vaccination | |
| Hoshino et al. | Rotavirus vaccine development for the prevention of severe diarrhea in infants and young children | |
| US4636385A (en) | Vaccine, method for its preparation, and use thereof in vaccinating humans against rotavirus infection | |
| Mackow et al. | Immunization with baculovirus-expressed VP4 protein passively protects against simian and murine rotavirus challenge | |
| KR0171434B1 (ko) | 인체 로타바이러스, 백신 및 방법 | |
| Pensaert et al. | Vaccination of chickens against a Belgian nephropathogenic strain of infectious bronchitis virus B1648 using attenuated homologous and heterologous strains | |
| Ward et al. | Serum-neutralizing antibody to VP4 and VP7 proteins in infants following vaccination with WC3 bovine rotavirus | |
| EP0603386B1 (de) | Parenterale immunisierung gegen rotavirus | |
| Feng et al. | Heterotypic protection following oral immunization with live heterologous rotaviruses in a mouse model | |
| SHIBATA et al. | Passive protection against porcine epidemic diarrhea (PED) virus in piglets by colostrum from immunized cows | |
| WO1994001134A9 (en) | Parenteral immunization against rotavirus | |
| Snodgrass et al. | Homotypic and heterotypic serological responses to rotavirus neutralization epitopes in immunologically naive and experienced animals | |
| Bishop et al. | Heterologous protection against rotavirus-induced disease in gnotobiotic piglets | |
| Nguyen et al. | Protection and antibody responses to oral priming by attenuated human rotavirus followed by oral boosting with 2/6-rotavirus-like particles with immunostimulating complexes in gnotobiotic pigs | |
| AU618973B2 (en) | Novel rotavirus reassortant vaccine | |
| Brüssow et al. | Neutralizing antibodies to heterologous animal rotavirus serotypes 5, 6, 7, and 10 in sera from Ecuadorian children | |
| Castrucci et al. | Comparative study of rotavirus strains of bovine and rabbit origin | |
| WO2007008905A1 (en) | Porcine rotavirus reassortant compositions | |
| Vesikari et al. | Clinical trials of rotavirus vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |